808 / 1851
Trial
N of
patients
IMRT Regimen
Toxicity Efficacy
ECOG 3205 61
some 5-FU/CisP +RT +
cetuximab
32%
G4
5%
G5
The 3-
year
LRF
23%
AMC045
HIV+
45
some NACT + 5-
FU/CisP +RT +
cetuximab
26%
G4
4%
G5
LRF
16%
Trials with Cetuximab in anal cancer
Garg MK, et al., J Clin Oncol. 2017 Jan 9: [Epub ahead of print]
Garg MK, et al., J Clin Oncol 34, 2016 (suppl; abstr 3522)